Retrophin Appoints Noah Rosenberg Chief Medical Officer

Noah Rosenberg has joined Retrophin (NASDAQ: [[ticker:RTRX]]) as chief medical officer. Rosenberg comes to the San Diego biotech from Fairfield, NJ-based Medimetriks Pharmaceuticals, where he was chief medical officer. Retrophin’s drug pipeline includes late-stage drug candidates fosmetpantotenate, an experimental treatment for the rare neurological disorder pantothenate kinase-associated neurodegeneration, and sparsentan, a drug for a rare kidney disease that Retrophin licensed from Ligand Pharmaceuticals (NASDAQ: [[ticker:LGND]]) in 2012.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.